Search CDR Drug Database

Results 1 - 187 of 187

  1. Abacavir / lamivudine

    Brand name Kivexa
    Manufacturer GlaxoSmithKline
    Indication HIV infection
    Submission type Initial
    Date submission received 2005-07-26
    Status Completed Submission status report
    Date recommendation issued 2005-12-07 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  2. Abatacept

    Brand name Orencia
    Manufacturer Bristol-Myers Squibb Canada
    Indication Arthritis, Rheumatoid
    Submission type Resubmission #1
    Date submission received 2009-12-02
    Status Active Submission status report

  3. Abatacept

    Brand name Orencia
    Manufacturer Bristol-Myers Squibb Canada
    Indication Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid
    Submission type New Indication
    Date submission received 2008-08-29
    Status Completed Submission status report
    Date recommendation issued 2009-04-22 Recommendation and reasons
    Recommendation List with criteria/condition

  4. Abatacept

    Brand name Orencia
    Manufacturer Bristol-Myers Squibb Canada
    Indication Arthritis, Rheumatoid
    Submission type Initial
    Date submission received 2006-10-26
    Status Completed Submission status report
    Date recommendation issued 2007-06-27 Recommendation and reasons
    Recommendation List with criteria/condition

  5. Acamprosate calcium

    Brand name Campral
    Manufacturer Prempharm Inc.
    Indication Alcohol Abstinence
    Submission type Request for Advice
    Date submission received 2008-07-22
    Status Completed Submission status report

  6. Acamprosate calcium

    Brand name Campral
    Manufacturer Prempharm Inc.
    Indication Alcohol Abstinence
    Submission type Initial
    Date submission received 2007-08-29
    Status Completed Submission status report
    Date recommendation issued 2008-03-27 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  7. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories, Limited
    Indication Psoriasis
    Submission type New Indication
    Date submission received 2008-04-15
    Status Completed Submission status report
    Date recommendation issued 2008-10-16 Recommendation and reasons
    Recommendation List with criteria/condition

  8. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories, Limited
    Indication Crohn's disease
    Submission type Resubmission #3
    Date submission received 2007-07-12
    Status Completed Submission status report
    Date recommendation issued 2007-12-19 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  9. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories, Limited
    Indication Ankylosing spondylitis (AS)
    Submission type Resubmission #2
    Date submission received 2006-11-17
    Status Completed Submission status report
    Date recommendation issued 2007-06-27 Recommendation and reasons
    Recommendation List with criteria/condition

  10. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories Limited
    Indication Arthritis, psoriatic
    Submission type Resubmission #1
    Date submission received 2006-06-21
    Status Completed Submission status report
    Date recommendation issued 2006-11-29 Recommendation and reasons
    Recommendation List with criteria/condition

  11. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories Limited
    Indication Arthritis, rheumatoid
    Submission type Initial
    Date submission received 2004-09-24
    Status Completed Submission status report
    Date recommendation issued 2005-02-11 Recommendation and reasons
    Recommendation List with criteria/condition

  12. Adefovir dipivoxil

    Brand name Hepsera
    Manufacturer gilead Sciences Canada Inc.
    Indication Hepatitis B
    Submission type Request for Advice
    Date submission received 2007-06-29
    Status Completed Submission status report
    Date recommendation issued 2007-10-18 Recommendation and reasons
    Recommendation List with criteria/condition

  13. Adefovir dipivoxil

    Brand name Hepsera
    Manufacturer Gilead Sciences Canada Inc.
    Indication Hepatitis B
    Submission type Initial
    Date submission received 2006-04-24
    Status Completed Submission status report
    Date recommendation issued 2006-11-29 Recommendation and reasons
    Recommendation Do not list

  14. Agalsidase alfa

    Brand name Replagal
    Manufacturer Transkaryotic Therapies Inc.
    Indication Fabry Disease
    Submission type Initial
    Date submission received 2004-02-19
    Status Completed Submission status report
    Date recommendation issued 2004-11-24 Recommendation and reasons
    Recommendation Do not list

  15. Agalsidase beta

    Brand name Fabrazyme
    Manufacturer Genzyme Canada
    Indication Fabry Disease
    Submission type Resubmission #1
    Date submission received 2004-12-10
    Status Completed Submission status report
    Date recommendation issued 2005-05-18 Recommendation and reasons
    Recommendation Do not list

  16. Agalsidase beta

    Brand name Fabrazyme
    Manufacturer Genzyme Canada
    Indication Fabry Disease
    Submission type Initial
    Date submission received 2004-02-24
    Status Completed Submission status report
    Date recommendation issued 2004-11-24 Recommendation and reasons
    Recommendation Do not list

  17. Alefacept

    Brand name Amevive
    Manufacturer Biogen Idec Canada Inc.
    Indication Psoriasis, moderate to severe chronic plaque
    Submission type Resubmission #1
    Date submission received 2006-02-28
    Status Completed Submission status report
    Date recommendation issued 2006-09-27 Recommendation and reasons
    Recommendation Do not list

  18. Alefacept

    Brand name Amevive
    Manufacturer Biogen Idec Canada Inc.
    Indication Psoriasis, moderate to severe chronic plaque
    Submission type Initial
    Date submission received 2004-11-16
    Status Completed Submission status report
    Date recommendation issued 2005-05-26 Recommendation and reasons
    Recommendation Do not list

  19. Alendronate sodium / cholecalciferol

    Brand name Fosavance 70/5600
    Manufacturer Merck Frosst Canda Ltd.
    Indication Osteoporosis
    Submission type Initial
    Date submission received 2008-12-18
    Status Completed Submission status report
    Date recommendation issued 2009-06-17 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  20. Alendronate sodium / cholecalciferol

    Brand name Fosavance
    Manufacturer Merck Frosst Canda Ltd.
    Indication Osteoporosis
    Submission type Initial
    Date submission received 2006-03-27
    Status Completed Submission status report
    Date recommendation issued 2006-09-27 Recommendation and reasons
    Recommendation Do not list

  21. Alglucosidase

    Brand name Myozyme
    Manufacturer Genzyme Canada Inc.
    Indication Pompe’s disease
    Submission type Initial
    Date submission received 2006-10-10
    Status Completed Submission status report
    Date recommendation issued 2007-06-14 Recommendation and reasons
    Recommendation List with criteria/condition

  22. Aliskiren

    Brand name Rasilez
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Hypertension
    Submission type Initial
    Date submission received 2007-11-30
    Status Completed Submission status report
    Date recommendation issued 2008-06-25 Recommendation and reasons
    Recommendation Do not list

  23. Almotriptan

    Brand name Axert
    Manufacturer Janssen-Ortho Inc.
    Indication Migraine
    Submission type Initial
    Date submission received 2003-12-24
    Status Completed Submission status report
    Date recommendation issued 2004-05-27 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  24. Ambrisentan

    Brand name Volibris
    Manufacturer GlaxoSmithKline Inc.
    Indication Pulmonary arterial hypertension (WHO class II and III)
    Submission type Initial
    Date submission received 2008-07-09
    Status Completed Submission status report
    Date recommendation issued 2008-12-17 Recommendation and reasons
    Recommendation List with criteria/condition

  25. Amlodipine besylate / atorvastatin calcium

    Brand name Caduet
    Manufacturer Pfizer Canada Inc.
    Indication Hypertension/ Dyslipidemia
    Submission type Initial
    Date submission received 2005-12-15
    Status Completed Submission status report
    Date recommendation issued 2006-05-17 Recommendation and reasons
    Recommendation List with criteria/condition

  26. Aprepitant

    Brand name Emend
    Manufacturer Merck Frosst Canada Ltd.
    Indication Chemotherapy induced Nausea and Vomiting
    Submission type Initial
    Date submission received 2007-08-29
    Status Completed Submission status report
    Date recommendation issued 2008-02-20 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  27. Aripiprazole

    Brand name Abilify
    Manufacturer Bristol-Myers Squibb Canada
    Indication Schizophrenia
    Submission type Initial
    Date submission received 2009-11-06
    Status Active Submission status report

  28. Atazanavir

    Brand name Reyataz
    Manufacturer Bristol Myers Squibb
    Indication HIV infection
    Submission type Initial
    Date submission received 2003-12-16
    Status Completed Submission status report
    Date recommendation issued 2004-05-27 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  29. Atomoxetine hydrochloride

    Brand name Strattera
    Manufacturer Eli Lilly Canada Inc.
    Indication Attention deficit hyperactivity disorder
    Submission type Request for Advice
    Date submission received 2006-09-25
    Status Completed Submission status report

  30. Atomoxetine hydrochloride

    Brand name Strattera
    Manufacturer Eli Lilly Canada Inc.
    Indication Attention deficit hyperactivity disorder
    Submission type Initial
    Date submission received 2005-01-25
    Status Completed Submission status report
    Date recommendation issued 2005-09-28 Recommendation and reasons
    Recommendation Do not list

  31. Brimonidine tartrate / timolol maleate

    Brand name Combigan Ophthalmic Solution
    Manufacturer Allergan Canada Inc.
    Indication Glaucoma
    Submission type Initial
    Date submission received 2003-12-15
    Status Completed Submission status report
    Date recommendation issued 2004-05-27 Recommendation and reasons
    Recommendation List with criteria/condition

  32. Brinzolamide and timolol maleate suspension

    Brand name Azarga
    Manufacturer Alcon Canada Inc.
    Indication Glaucoma and Ocular hypertension
    Submission type Initial
    Date submission received 2009-08-28
    Status Completed Submission status report
    Date recommendation issued 2010-02-18 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  33. Buprenorphine / naloxone

    Brand name Suboxone
    Manufacturer Schering-Plough Canada Inc
    Indication Opioid drug dependence (Substitution treatment)
    Submission type Initial
    Date submission received 2008-03-06
    Status Completed Submission status report
    Date recommendation issued 2008-09-24 Recommendation and reasons
    Recommendation List with criteria/condition

  34. Butoconazole nitrate

    Brand name Gynazole.1
    Manufacturer Ferring Pharmaceuticals
    Indication Vaginal infection
    Submission type Initial
    Date submission received 2004-06-30
    Status Completed Submission status report
    Date recommendation issued 2005-01-26 Recommendation and reasons
    Recommendation Do not list

  35. Carbidopa, levodopa and entacapone

    Brand name Stalevo
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Parkinsons Disease
    Submission type Initial
    Date submission received 2008-04-15
    Status Completed Submission status report
    Date recommendation issued 2008-10-16 Recommendation and reasons
    Recommendation List in a similar manner

  36. Certolizumab pegol

    Brand name Cimzia
    Manufacturer UCB Pharma Canada Inc.
    Indication Arthritis, rheumatoid
    Submission type Initial
    Date submission received 2009-09-03
    Status Active Submission status report

  37. Ciclesonide

    Brand name Alvesco
    Manufacturer Altana Pharma Inc.
    Indication asthma
    Submission type Initial
    Date submission received 2006-07-24
    Status Completed Submission status report
    Date recommendation issued 2006-12-20 Recommendation and reasons
    Recommendation List

  38. Ciclesonide nasal spray

    Brand name Omnaris
    Manufacturer Nycomed Canada Inc.
    Indication Allergic Rhinitis (seasonal and perennial)
    Submission type Initial
    Date submission received 2008-05-07
    Status Completed Submission status report
    Date recommendation issued 2008-11-12 Recommendation and reasons
    Recommendation Do not list

  39. Cinacalcet hydrochloride

    Brand name Sensipar
    Manufacturer Amgen Canada Inc.
    Indication Secondary hyper-parathyroidism in chronic kidney disease
    Submission type Initial
    Date submission received 2004-08-20
    Status Completed Submission status report
    Date recommendation issued 2005-03-23 Recommendation and reasons
    Recommendation Do not list

  40. Ciprofloxacin hydrochloride & dexamethasone otic suspension

    Brand name Ciprodex
    Manufacturer Alcon Canada Inc.
    Indication Otitis media with otorrhea & otitis externa, acute
    Submission type Request for Advice
    Date submission received 2007-06-15
    Status Completed Submission status report
    Date recommendation issued 2007-10-18 Recommendation and reasons
    Recommendation List with criteria/condition

  41. Ciprofloxacin hydrochloride and dexamethasone otic suspension

    Brand name Ciprodex
    Manufacturer Alcon Canada Inc.
    Indication Otitis media with otorrhea & otitis externa, acute
    Submission type Initial
    Date submission received 2004-06-11
    Status Completed Submission status report
    Date recommendation issued 2005-01-26 Recommendation and reasons
    Recommendation Do not list

  42. Clostridium botulinum neurotoxin type A, free from complexing proteins

    Brand name Xeomin
    Manufacturer Merz Pharmaceuticals GmbH
    Indication Cervical Dystonia
    Submission type Initial
    Date submission received 2009-06-12
    Status Completed Submission status report
    Date recommendation issued 2009-12-16 Recommendation and reasons
    Recommendation List in a similar manner

  43. Clostridium botulinum neurotoxin type A, free from complexing proteins

    Brand name Xeomin
    Manufacturer Merz Pharmaceuticals GmbH
    Indication Blepharospasm
    Submission type Initial
    Date submission received 2009-06-12
    Status Completed Submission status report
    Date recommendation issued 2009-12-16 Recommendation and reasons
    Recommendation List in a similar manner

  44. Clostridium botulinum neurotoxin type A, free from complexing proteins

    Brand name Xeomin
    Manufacturer Merz Pharmaceuticals GmbH
    Indication Post-stroke Spasticity
    Submission type Initial
    Date submission received 2009-06-12
    Status Completed Submission status report
    Date recommendation issued 2009-12-16 Recommendation and reasons
    Recommendation Do not list

  45. Dabigatran etexilate

    Brand name Pradax
    Manufacturer Boehringer Ingelheim (Canada) Ltd.
    Indication Venous thromboembolism prevention
    Submission type Initial
    Date submission received 2008-07-08
    Status Completed Submission status report
    Date recommendation issued 2009-01-28 Recommendation and reasons
    Recommendation Do not list

  46. Daptomycin

    Brand name Cubicin
    Manufacturer Cubist Pharmaceuticals Inc.
    Indication Skin and Skin Structure Infections & Bacteremia
    Submission type Initial
    Date submission received 2008-03-06
    Status Completed Submission status report
    Date recommendation issued 2008-09-24 Recommendation and reasons
    Recommendation Do not list

  47. Darifenacin hydrobromide

    Brand name Enablex
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Bladder, overactive
    Submission type Resubmission #1
    Date submission received 2008-10-01
    Status Completed Submission status report
    Date recommendation issued 2009-04-16 Recommendation and reasons
    Recommendation List with criteria/condition

  48. Darifenacin hydrobromide

    Brand name Enablex
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Bladder, overactive
    Submission type Initial
    Date submission received 2006-04-26
    Status Completed Submission status report
    Date recommendation issued 2006-10-19 Recommendation and reasons
    Recommendation Do not list

  49. Darunavir

    Brand name Prezista
    Manufacturer Janssen-Ortho Inc.
    Indication HIV infection (Pediatric)
    Submission type New Indication
    Date submission received 2009-12-22
    Status Active Submission status report

  50. Darunavir

    Brand name Prezista
    Manufacturer Janssen-Ortho Inc.
    Indication HIV - treatment naive
    Submission type New Indication
    Date submission received 2009-03-27
    Status Completed Submission status report
    Date recommendation issued 2009-10-14 Recommendation and reasons
    Recommendation List with criteria/condition

  51. Darunavir

    Brand name Prezista
    Manufacturer Janssen-Ortho Inc.
    Indication HIV infection
    Submission type Initial
    Date submission received 2006-08-29
    Status Completed Submission status report
    Date recommendation issued 2007-02-14 Recommendation and reasons
    Recommendation List with criteria/condition

  52. Deferasirox

    Brand name Exjade
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Iron overload
    Submission type Initial
    Date submission received 2006-10-26
    Status Completed Submission status report
    Date recommendation issued 2007-04-19 Recommendation and reasons
    Recommendation List with criteria/condition

  53. Delta-9-tetrahydrocannabinol / cannabidiol

    Brand name Sativex
    Manufacturer GW Pharma Ltd.
    Indication Cancer Pain (adjunctive analgesia to maximum tolerated strong opioids)
    Submission type Resubmission #1
    Date submission received 2007-08-07
    Status Completed Submission status report
    Date recommendation issued 2008-02-20 Recommendation and reasons
    Recommendation Do not list

  54. Delta-9-tetrahydrocannabinol / cannabidiol

    Brand name Sativex
    Manufacturer GW Pharma Ltd.
    Indication Neuropathic pain (adjunctive) in MS.
    Submission type Initial
    Date submission received 2007-02-27
    Status Completed Submission status report
    Date recommendation issued 2007-09-26 Recommendation and reasons
    Recommendation Do not list

  55. Desvenlafaxine succinate

    Brand name Pristiq
    Manufacturer Wyeth Canada
    Indication Major Depressive Disorder (MDD)
    Submission type Initial
    Date submission received 2009-03-05
    Status Completed Submission status report
    Date recommendation issued 2009-09-23 Recommendation and reasons
    Recommendation Do not list

  56. Dronedarone hydrochloride

    Brand name Multaq
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication Atrial fibrillation
    Submission type Initial
    Date submission received 2009-09-18
    Status Active Submission status report

  57. Drospirenone / ethinyl estradiol

    Brand name Yasmin
    Manufacturer Berlex Canada Inc.
    Indication Contraceptive, oral
    Submission type Initial
    Date submission received 2005-01-20
    Status Completed Submission status report
    Date recommendation issued 2005-06-16 Recommendation and reasons
    Recommendation List

  58. Duloxetine hydrochloride

    Brand name Cymbalta
    Manufacturer Eli Lilly Canada Inc.
    Indication Major Depressive Disorder (MDD)
    Submission type Initial
    Date submission received 2008-02-08
    Status Completed Submission status report
    Date recommendation issued 2008-08-14 Recommendation and reasons
    Recommendation Do not list

  59. Duloxetine hydrochloride

    Brand name Cymbalta
    Manufacturer Eli Lilly Canada Inc.
    Indication Neuropathic pain, Diabetic
    Submission type Initial
    Date submission received 2008-02-08
    Status Completed Submission status report
    Date recommendation issued 2008-08-14 Recommendation and reasons
    Recommendation List with criteria/condition

  60. Dutasteride

    Brand name Avodart
    Manufacturer GlaxoSmithKline Inc.
    Indication Prostatic hyperplasia, benign
    Submission type Initial
    Date submission received 2004-08-24
    Status Completed Submission status report
    Date recommendation issued 2005-01-20 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  61. Eculizumab

    Brand name Soliris
    Manufacturer Alexion Pharmaceuticals Inc.
    Indication Paroxysmal nocturnal hemoglobinuria (PNH)
    Submission type Initial
    Date submission received 2009-09-18
    Status Completed Submission status report
    Date recommendation issued 2010-02-18 Recommendation and reasons
    Recommendation Do not list

  62. Efalizumab

    Brand name Raptiva
    Manufacturer Serono Canada Inc.
    Indication Psoriasis, moderate to severe chronic plaque
    Submission type Request for Advice
    Date submission received 2007-06-19
    Status Completed Submission status report

  63. Efalizumab

    Brand name Raptiva
    Manufacturer Serono Canada Inc.
    Indication Psoriasis, moderate to severe chronic plaque
    Submission type Initial
    Date submission received 2005-10-25
    Status Completed Submission status report
    Date recommendation issued 2006-08-24 Recommendation and reasons
    Recommendation List with criteria/condition

  64. Efavirenz, emtricitabine, tenofovir disoproxil fumarate

    Brand name Atripla
    Manufacturer Bristol-Myers Squibb and Gilead Sciences
    Indication HIV
    Submission type Initial
    Date submission received 2007-10-30
    Status Completed Submission status report
    Date recommendation issued 2008-04-17 Recommendation and reasons
    Recommendation List with criteria/condition

  65. Eletriptan hydrobromide

    Brand name Relpax
    Manufacturer Pfizer Canada Inc.
    Indication Migraine
    Submission type Initial
    Date submission received 2004-09-21
    Status Completed Submission status report
    Date recommendation issued 2005-03-23 Recommendation and reasons
    Recommendation Do not list

  66. Emtricitabine / tenofovir disoproxil fumarate

    Brand name Truvada
    Manufacturer Gilead Sciences Canada Inc.
    Indication HIV infection
    Submission type Request for Advice
    Date submission received 2008-07-07
    Status Completed Submission status report
    Date recommendation issued 2008-12-17 Recommendation and reasons
    Recommendation List with criteria/condition

  67. Emtricitabine / tenofovir disoproxil fumarate

    Updated recommendation issued 2008-12-17 Recommendation and reasons
    Brand name Truvada
    Manufacturer Gilead Sciences Canada Inc.
    Indication HIV infection
    Submission type Initial
    Date submission received 2006-05-29
    Status Completed Submission status report
    Date recommendation issued 2006-10-25 Recommendation and reasons
    Recommendation List with criteria/condition

  68. Entecavir

    Brand name Baraclude
    Manufacturer Bristol-Myers Squibb Canada
    Indication Hepatitis B (chronic)
    Submission type Initial
    Date submission received 2006-12-12
    Status Completed Submission status report
    Date recommendation issued 2007-11-28 Recommendation and reasons
    Recommendation List with criteria/condition

  69. Eplerenone

    Brand name Inspra
    Manufacturer Pfizer Canada Inc.
    Indication Post myocardial infarction
    Submission type Initial
    Date submission received 2009-05-06
    Status Completed Submission status report
    Date recommendation issued 2009-11-25 Recommendation and reasons
    Recommendation Do not list

  70. Eprosartan mesylate / hydrochlorothiazide

    Brand name Teveten Plus
    Manufacturer Solvay Pharma Inc.
    Indication High blood pressure
    Submission type Initial
    Date submission received 2004-07-08
    Status Completed Submission status report
    Date recommendation issued 2004-12-15 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  71. Erlotinib

    Brand name Tarceva
    Manufacturer Hoffmann-La Roche Limited
    Indication Lung cancer, non-small cell
    Submission type Initial
    Date submission received 2005-07-19
    Status Completed Submission status report
    Date recommendation issued 2005-12-07 Recommendation and reasons
    Recommendation List with criteria/condition

  72. Escitalopram oxalate

    Brand name Cipralex
    Manufacturer Lundbeck Canada Inc.
    Indication Depression, Major Depressive Disorder (MDD)
    Submission type Resubmission #1
    Date submission received 2006-06-08
    Status Completed Submission status report
    Date recommendation issued 2007-01-24 Recommendation and reasons
    Recommendation Do not list

  73. Escitalopram oxalate

    Brand name Cipralex
    Manufacturer Lundbeck Canada Inc.
    Indication Depression, Major Depressive Disorder (MDD)
    Submission type Initial
    Date submission received 2005-08-03
    Status Withdrawn Submission status report

  74. Etonogestrel / ethinyl estradiol

    Brand name NuvaRing
    Manufacturer Organon Canada Ltd.
    Indication Contraceptive, ring
    Submission type Initial
    Date submission received 2006-05-05
    Status Completed Submission status report
    Date recommendation issued 2006-11-29 Recommendation and reasons
    Recommendation List with criteria/condition

  75. Etravirine

    Brand name Intelence
    Manufacturer Janssen-Ortho Inc.
    Indication HIV
    Submission type Initial
    Date submission received 2008-04-02
    Status Completed Submission status report
    Date recommendation issued 2008-08-14 Recommendation and reasons
    Recommendation List with criteria/condition

  76. Fosamprenavir calcium

    Brand name Telzir
    Manufacturer GlaxoSmithKline Inc.
    Indication HIV infection
    Submission type Initial
    Date submission received 2005-01-24
    Status Completed Submission status report
    Date recommendation issued 2005-06-16 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  77. Gefitinib

    Brand name Iressa
    Manufacturer AstraZeneca
    Indication Lung cancer, non-small cell
    Submission type Initial
    Date submission received 2003-12-22
    Status Completed Submission status report
    Date recommendation issued 2004-06-23 Recommendation and reasons
    Recommendation Do not list

  78. Glatiramer acetate

    Brand name Copaxone
    Manufacturer Teva Pharmaceutical Industries Ltd.
    Indication Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis
    Submission type New Indication
    Date submission received 2009-04-29
    Status Completed Submission status report
    Date recommendation issued 2009-11-25 Recommendation and reasons
    Recommendation Do not list

  79. Golimumab

    Brand name Simponi
    Manufacturer Centocor Inc.
    Indication Ankylosing spondylitis
    Submission type Initial
    Date submission received 2009-09-03
    Status Active Submission status report

  80. Golimumab

    Brand name Simponi
    Manufacturer Centocor Inc.
    Indication Arthritis, rheumatoid
    Submission type Initial
    Date submission received 2009-09-03
    Status Active Submission status report

  81. Golimumab

    Brand name Simponi
    Manufacturer Centocor Inc.
    Indication Arthritis, psoriatic
    Submission type Initial
    Date submission received 2009-09-03
    Status Active Submission status report

  82. Histrelin acetate

    Brand name Vantas
    Manufacturer Paladin Labs Inc.
    Indication Prostate Cancer
    Submission type Initial
    Date submission received 2006-09-20
    Status Completed Submission status report
    Date recommendation issued 2007-04-26 Recommendation and reasons
    Recommendation Do not list

  83. Hydromorphone hydrochloride

    Brand name Jurnista
    Manufacturer Janssen-Ortho Inc.
    Indication Chronic Pain (moderate to severe)
    Submission type Initial
    Date submission received 2009-12-04
    Status Active Submission status report

  84. Idursulfase

    Brand name Elaprase
    Manufacturer Shire Human Genetic Therapies, Inc.
    Indication Mucopolysarccharidosis II (MPS II), Hunter Syndrome
    Submission type Initial
    Date submission received 2007-07-13
    Status Completed Submission status report
    Date recommendation issued 2007-12-19 Recommendation and reasons
    Recommendation Do not list

  85. Infliximab

    Brand name Remicade
    Manufacturer Centocor Inc.
    Indication Ulcerative Colitis
    Submission type Initial
    Date submission received 2008-09-29
    Status Completed Submission status report
    Date recommendation issued 2009-04-22 Recommendation and reasons
    Recommendation Do not list

  86. Insulin aspart / insulin aspart protamine

    Brand name NovoMix 30
    Manufacturer Novo Nordisk Canada Inc.
    Indication Diabetes mellitus
    Submission type Initial
    Date submission received 2005-10-13
    Status Completed Submission status report
    Date recommendation issued 2006-04-26 Recommendation and reasons
    Recommendation Do not list

  87. Insulin detemir

    Brand name Levemir
    Manufacturer Novo Nordisk Canada Inc.
    Indication Diabetes Mellitus Type1, Pediatrics
    Submission type New Indication
    Date submission received 2009-03-10
    Status Completed Submission status report
    Date recommendation issued 2009-08-19 Recommendation and reasons
    Recommendation Do not list

  88. Insulin detemir

    Brand name Levemir
    Manufacturer Novo Nordisk Canada Inc.
    Indication Diabetes mellitus
    Submission type Resubmission #2
    Date submission received 2009-03-10
    Status Completed Submission status report
    Date recommendation issued 2009-08-19 Recommendation and reasons
    Recommendation Do not list

  89. Insulin detemir

    Brand name Levemir
    Manufacturer Novo Nordisk Canada Inc.
    Indication Diabetes mellitus
    Submission type Resubmission #1
    Date submission received 2009-02-02
    Status Withdrawn Submission status report

  90. Insulin detemir

    Brand name Levemir
    Manufacturer Novo Nordisk Canada Inc.
    Indication Diabetes mellitus
    Submission type Initial
    Date submission received 2005-12-19
    Status Completed Submission status report
    Date recommendation issued 2006-08-02 Recommendation and reasons
    Recommendation Do not list

  91. Insulin glargine (rDNA origin)

    Brand name Lantus
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication Diabetes, Type 1 & 2
    Submission type Request for Advice
    Date submission received 2009-06-09
    Status Completed Submission status report

  92. Insulin glargine (rDNA origin)

    Brand name Lantus
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication Diabetes, Type 1 & 2
    Submission type Resubmission #1
    Date submission received 2006-03-27
    Status Completed Submission status report
    Date recommendation issued 2006-10-25 Recommendation and reasons
    Recommendation Do not list

  93. Insulin glargine (rDNA origin)

    Brand name Lantus
    Manufacturer Aventis Pharma Inc.
    Indication Diabetes, Type 1 & 2
    Submission type Initial
    Date submission received 2005-02-11
    Status Completed Submission status report
    Date recommendation issued 2005-09-28 Recommendation and reasons
    Recommendation Do not list

  94. Insulin glulisine

    Brand name Apidra
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication Diabetes (Type 1 & 2)
    Submission type Initial
    Date submission received 2008-08-29
    Status Completed Submission status report
    Date recommendation issued 2009-02-19 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  95. Lanreotide acetate

    Brand name Somatuline Autogel
    Manufacturer Ipsen Limited
    Indication Acromegaly
    Submission type Initial
    Date submission received 2007-02-20
    Status Completed Submission status report
    Date recommendation issued 2007-07-19 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  96. Lanthanum carbonate hydrate

    Brand name Fosrenol
    Manufacturer Shire BioChem Inc.
    Indication Hyperphosphatemia, end-stage renal disease
    Submission type Initial
    Date submission received 2007-06-28
    Status Completed Submission status report
    Date recommendation issued 2008-01-30 Recommendation and reasons
    Recommendation Do not list

  97. Laronidase

    Brand name Aldurazyme
    Manufacturer Genzyme Canada
    Indication Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie
    Submission type Initial
    Date submission received 2005-02-03
    Status Completed Submission status report
    Date recommendation issued 2005-07-14 Recommendation and reasons
    Recommendation Do not list

  98. Levodopa / carbidopa

    Brand name Duodopa
    Manufacturer Solvay Pharma Inc.
    Indication Parkinson's disease
    Submission type Initial
    Date submission received 2008-12-19
    Status Completed Submission status report
    Date recommendation issued 2009-07-22 Recommendation and reasons
    Recommendation Do not list

  99. Lisdexamfetamine dimesylate

    Brand name Vyvanse
    Manufacturer Shire Canada Inc.
    Indication Attention deficit hyperactivity disorder
    Submission type Initial
    Date submission received 2009-07-10
    Status Completed Submission status report
    Date recommendation issued 2009-12-18 Recommendation and reasons
    Recommendation Do not list

  100. Loteprednol etabonate

    Brand name Lotemax
    Manufacturer Bausch & Lomb
    Indication Post-operative inflammation following cataract surgery
    Submission type Initial
    Date submission received 2009-12-02
    Status Active Submission status report

  101. Lumiracoxib

    Brand name Prexige
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Osteoarthritis (Knee)
    Submission type Initial
    Date submission received 2006-12-15
    Status Completed Submission status report
    Date recommendation issued 2007-07-25 Recommendation and reasons
    Recommendation Do not list

  102. Maraviroc

    Brand name Celsentri
    Manufacturer Pfizer Canada Inc.
    Indication HIV
    Submission type Resubmission #1
    Date submission received 2008-05-07
    Status Completed Submission status report
    Date recommendation issued 2008-11-12 Recommendation and reasons
    Recommendation List with criteria/condition

  103. Maraviroc

    Brand name Celsentri
    Manufacturer Pfizer Canada Inc.
    Indication HIV
    Submission type Initial
    Date submission received 2007-11-02
    Status Withdrawn Submission status report

  104. Memantine hydrochloride

    Brand name Ebixa
    Manufacturer Lundbeck Canada Inc.
    Indication Dementia of the Alzheimer type, moderate to severe
    Submission type Initial
    Date submission received 2004-12-21
    Status Completed Submission status report
    Date recommendation issued 2005-11-23 Recommendation and reasons
    Recommendation Do not list

  105. Methylnaltrexone bromide

    Brand name Relistor
    Manufacturer Wyeth Canada
    Indication Constipation, Opioid-induced
    Submission type Initial
    Date submission received 2008-05-07
    Status Completed Submission status report
    Date recommendation issued 2009-01-28 Recommendation and reasons
    Recommendation Do not list

  106. Miglustat

    Brand name Zavesca
    Manufacturer Actelion Pharmaceuticals Canada Inc.
    Indication Gaucher disease
    Submission type Initial
    Date submission received 2004-05-13
    Status Completed Submission status report
    Date recommendation issued 2004-11-24 Recommendation and reasons
    Recommendation Do not list

  107. Mixed amphetamine salts

    Brand name Adderall XR
    Manufacturer Shire Canada Inc.
    Indication Attention deficit hyperactivity disorder, Adult
    Submission type New Indication
    Date submission received 2007-11-29
    Status Completed Submission status report
    Date recommendation issued 2008-06-25 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  108. Mixed amphetamine salts

    Brand name Adderall XR
    Manufacturer Shire BioChem Inc.
    Indication Attention deficit hyperactivity disorder
    Submission type Resubmission #1
    Date submission received 2004-12-15
    Status Withdrawn Submission status report

  109. Mixed amphetamine salts

    Brand name Adderall XR
    Manufacturer Shire BioChem Inc.
    Indication Attention deficit hyperactivity disorder
    Submission type Initial
    Date submission received 2004-04-13
    Status Completed Submission status report
    Date recommendation issued 2004-11-24 Recommendation and reasons
    Recommendation Do not list

  110. Mycophenolate sodium

    Brand name Myfortic
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Prophylaxis of organ rejection in allogeneic renal transplants
    Submission type Initial
    Date submission received 2005-03-03
    Status Completed Submission status report
    Date recommendation issued 2005-07-08 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  111. Natalizumab

    Brand name Tysabri
    Manufacturer Biogen Idec Canada Inc.
    Indication Multiple Sclerosis, relapsing-remitting
    Submission type Resubmission #1
    Date submission received 2008-05-06
    Status Completed Submission status report
    Date recommendation issued 2009-02-25 Recommendation and reasons
    Recommendation List with criteria/condition

  112. Natalizumab

    Brand name Tysabri
    Manufacturer Biogen Idec Canada Inc.
    Indication Multiple Sclerosis, relapsing-remitting
    Submission type Initial
    Date submission received 2006-10-26
    Status Completed Submission status report
    Date recommendation issued 2007-04-26 Recommendation and reasons
    Recommendation Do not list

  113. Niacin / lovastatin

    Brand name Advicor
    Manufacturer Oryx Pharmaceuticals Inc.
    Indication Hypercholesterolemia and mixed dyslipidemia
    Submission type Initial
    Date submission received 2005-10-18
    Status Completed Submission status report
    Date recommendation issued 2006-04-26 Recommendation and reasons
    Recommendation List

  114. Norgelestromin / ethinyl estradiol

    Brand name Evra
    Manufacturer Janssen-Ortho Inc.
    Indication Contraceptive, patch
    Submission type Initial
    Date submission received 2003-12-19
    Status Completed Submission status report
    Date recommendation issued 2004-06-23 Recommendation and reasons
    Recommendation Do not list

  115. Olmesartan medoxomil

    Brand name Olmetec
    Manufacturer Schering-Plough Canada Inc.
    Indication Hypertension
    Submission type Initial
    Date submission received 2008-11-28
    Status Completed Submission status report
    Date recommendation issued 2009-05-27 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  116. Olmesartan medoxomil + hydrochlorothiazide

    Brand name Olmetec Plus
    Manufacturer Schering-Plough Canada Inc.
    Indication Hypertension
    Submission type Initial
    Date submission received 2008-11-28
    Status Completed Submission status report
    Date recommendation issued 2009-05-27 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  117. Omalizumab

    Brand name Xolair
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Asthma, severe persistent
    Submission type Resubmission #1
    Date submission received 2005-10-13
    Status Completed Submission status report
    Date recommendation issued 2006-03-07 Recommendation and reasons
    Recommendation Do not list

  118. Omalizumab

    Brand name Xolair
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Asthma, severe persistent
    Submission type Initial
    Date submission received 2005-04-18
    Status Suspended Submission status report

  119. Paliperidone

    Brand name Invega
    Manufacturer Janssen-Ortho Inc.
    Indication Schizophrenia
    Submission type Initial
    Date submission received 2007-11-01
    Status Completed Submission status report
    Date recommendation issued 2008-05-28 Recommendation and reasons
    Recommendation Do not list

  120. Pantoprazole magnesium

    Brand name Pantoloc M
    Manufacturer Altana Pharma Inc.
    Indication Gastric acid secretion, reduction of
    Submission type Initial
    Date submission received 2006-03-17
    Status Completed Submission status report
    Date recommendation issued 2006-07-20 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  121. Pegaptanib sodium

    Brand name Macugen
    Manufacturer Pfizer Canada Inc.
    Indication Macular degeneration, age-related
    Submission type Initial
    Date submission received 2005-10-20
    Status Completed Submission status report
    Date recommendation issued 2006-05-25 Recommendation and reasons
    Recommendation Do not list

  122. Pegfilgrastim

    Brand name Neulasta
    Manufacturer Amgen Canada Inc.
    Indication Neutropenia
    Submission type Initial
    Date submission received 2004-03-29
    Status Completed Submission status report
    Date recommendation issued 2004-10-27 Recommendation and reasons
    Recommendation List with criteria/condition

  123. Peginterferon alfa-2a and Ribavirin

    Brand name Pegasys RBV
    Manufacturer Hoffman-La Roche Ltd.
    Indication Hepatitis C, chronic
    Submission type Initial
    Date submission received 2004-05-14
    Status Completed Submission status report
    Date recommendation issued 2004-10-14 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  124. Pegvisomant

    Brand name Somavert
    Manufacturer Pfizer Canada Inc.
    Indication acromegaly
    Submission type Initial
    Date submission received 2006-01-25
    Status Completed Submission status report
    Date recommendation issued 2006-08-02 Recommendation and reasons
    Recommendation Do not list

  125. Penciclovir

    Brand name Denavir
    Manufacturer Novartis Consumer Health Care Inc.
    Indication Herpes labialis (cold sores)
    Submission type Initial
    Date submission received 2006-09-20
    Status Completed Submission status report
    Date recommendation issued 2007-04-26 Recommendation and reasons
    Recommendation Do not list

  126. Posaconazole

    Brand name Spriafil
    Manufacturer Schering-Plough Canada Inc.
    Indication Aspergillus and Candida infections
    Submission type Initial
    Date submission received 2007-05-24
    Status Completed Submission status report
    Date recommendation issued 2008-01-30 Recommendation and reasons
    Recommendation Do not list

  127. Pregabalin

    Brand name Lyrica
    Manufacturer Pfizer Canada Inc.
    Indication diabetic peripheral neuropathy
    Submission type Resubmission #1
    Date submission received 2009-03-20
    Status Completed Submission status report
    Date recommendation issued 2009-09-23 Recommendation and reasons
    Recommendation Do not list

  128. Pregabalin

    Brand name Lyrica
    Manufacturer Pfizer Canada Inc.
    Indication Neuropathic pain
    Submission type Initial
    Date submission received 2005-06-27
    Status Completed Submission status report
    Date recommendation issued 2006-01-25 Recommendation and reasons
    Recommendation Do not list

  129. Quinagolide hydrochloride

    Brand name Norprolac
    Manufacturer Ferring Pharmaceuticals
    Indication Hyperprolactinemia
    Submission type Resubmission #1
    Date submission received 2005-11-23
    Status Completed Submission status report
    Date recommendation issued 2006-05-17 Recommendation and reasons
    Recommendation List with criteria/condition

  130. Quinagolide hydrochloride

    Brand name Norprolac
    Manufacturer Ferring Pharmaceuticals
    Indication Hyperprolactinemia
    Submission type Initial
    Date submission received 2004-12-16
    Status Completed Submission status report
    Date recommendation issued 2005-09-28 Recommendation and reasons
    Recommendation Do not list

  131. Raltegravir

    Brand name Isentress
    Manufacturer Merck Frosst Canada Ltd.
    Indication HIV (treatment naïve and treatment experienced)
    Submission type New Indication
    Date submission received 2009-12-04
    Status Active Submission status report

  132. Raltegravir

    Brand name Isentress
    Manufacturer Merck Frosst Canada Ltd.
    Indication HIV
    Submission type Initial
    Date submission received 2007-11-29
    Status Completed Submission status report
    Date recommendation issued 2008-05-14 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  133. Ramipril / felodipine extended release

    Brand name Altace Plus Felodipine
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication Hypertension
    Submission type Initial
    Date submission received 2006-06-22
    Status Completed Submission status report
    Date recommendation issued 2006-11-15 Recommendation and reasons
    Recommendation Do not list

  134. Ramipril / hydrochlorothiazide

    Brand name Altace HCT
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication Hypertension
    Submission type Resubmission #1
    Date submission received 2007-03-26
    Status Completed Submission status report
    Date recommendation issued 2007-06-14 Recommendation and reasons
    Recommendation List

  135. Ramipril / hydrochlorothiazide

    Brand name Altace HCT
    Manufacturer Sanofi –Aventis Canada inc.
    Indication Hypertension
    Submission type Initial
    Date submission received 2006-10-26
    Status Suspended Submission status report

  136. Ranibizumab

    Brand name Lucentis
    Manufacturer Novartis Pharmaceuticals Inc.
    Indication Macular degeneration, age-related
    Submission type Initial
    Date submission received 2007-07-12
    Status Completed Submission status report
    Date recommendation issued 2008-03-27 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  137. Rasagiline mesylate

    Brand name Azilect
    Manufacturer Teva Pharmaceuticals Industries Ltd.
    Indication Parkinson’s disease
    Submission type Request for Advice
    Date submission received 2009-03-10
    Status Completed Submission status report

  138. Rasagiline mesylate

    Brand name Azilect
    Manufacturer Teva Neurosciences
    Indication Parkinson's disease
    Submission type Initial
    Date submission received 2006-09-01
    Status Completed Submission status report
    Date recommendation issued 2007-03-28 Recommendation and reasons
    Recommendation Do not list

  139. Rituximab

    Brand name Rituxan
    Manufacturer Hoffmann-La Roche Limited
    Indication Arthritis, rheumatoid
    Submission type Initial
    Date submission received 2006-06-26
    Status Completed Submission status report
    Date recommendation issued 2007-02-14 Recommendation and reasons
    Recommendation List with criteria/condition

  140. Rivaroxaban

    Brand name Xarelto
    Manufacturer Bayer Inc.
    Indication Venous thromboembolism prevention
    Submission type Initial
    Date submission received 2008-05-07
    Status Completed Submission status report
    Date recommendation issued 2008-12-17 Recommendation and reasons
    Recommendation List with criteria/condition

  141. Rivastigmine

    Brand name Exelon Patch
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Dementia (Alzheimer's type)
    Submission type Initial
    Date submission received 2007-12-21
    Status Completed Submission status report
    Date recommendation issued 2008-07-23 Recommendation and reasons
    Recommendation Do not list

  142. Romiplostim

    Brand name Nplate
    Manufacturer Amgen Canada Inc.
    Indication Chronic immune (idiopathic) thrombocytopenic purpura (ITP)
    Submission type Initial
    Date submission received 2009-09-29
    Status Active Submission status report

  143. Saxagliptin

    Brand name Onglyza
    Manufacturer Bristol-Myers Squibb Canada
    Indication Diabetes Mellitus (Type 2)
    Submission type Initial
    Date submission received 2009-11-09
    Status Active Submission status report

  144. Sildenafil citrate

    Brand name Revatio
    Manufacturer Pfizer Canada Inc.
    Indication Pulmonary arterial hypertension (WHO class II and III)
    Submission type Initial
    Date submission received 2006-09-20
    Status Completed Submission status report
    Date recommendation issued 2007-02-14 Recommendation and reasons
    Recommendation List in a similar manner

  145. Sitagliptin phosphate

    Brand name Januvia
    Manufacturer Merck Frosst Canada Ltd.
    Indication Diabetes Mellitus (Type 2)
    Submission type Resubmission #1
    Date submission received 2009-10-29
    Status Active Submission status report

  146. Sitagliptin phosphate

    Brand name Januvia
    Manufacturer Merck Frosst Canada Ltd.
    Indication Diabetes Mellitus (Type 2)
    Submission type Initial
    Date submission received 2007-12-20
    Status Completed Submission status report
    Date recommendation issued 2008-06-18 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  147. Sitagliptin phosphate monohydrate / metformin hydrochloride

    Brand name Janumet
    Manufacturer Merck Frosst Canada Ltd.
    Indication Diabetes Mellitus (Type 2)
    Submission type Initial
    Date submission received 2009-11-04
    Status Active Submission status report

  148. Sitaxsentan sodium

    Brand name Thelin
    Manufacturer Encysive Canada Inc.
    Indication Pulmonary arterial hypertension (WHO class II and III)
    Submission type Resubmission #1
    Date submission received 2008-05-05
    Status Completed Submission status report
    Date recommendation issued 2009-01-28 Recommendation and reasons
    Recommendation Do not list

  149. Sitaxsentan sodium

    Brand name Thelin
    Manufacturer Encysive Canada Inc.
    Indication Pulmonary arterial hypertension (WHO class II and III)
    Submission type Initial
    Date submission received 2007-06-22
    Status Completed Submission status report
    Date recommendation issued 2008-01-30 Recommendation and reasons
    Recommendation Do not list

  150. Sodium oxybate

    Brand name Xyrem
    Manufacturer Valeant Canada Ltd.
    Indication Narcolepsy
    Submission type Resubmission #1
    Date submission received 2008-07-09
    Status Completed Submission status report
    Date recommendation issued 2009-01-28 Recommendation and reasons
    Recommendation Do not list

  151. Sodium oxybate

    Brand name Xyrem
    Manufacturer Valeant Canada Ltd.
    Indication Narcolepsy
    Submission type Initial
    Date submission received 2007-08-29
    Status Withdrawn Submission status report

  152. Solifenacin succinate

    Brand name Vesicare
    Manufacturer Astellas Pharma Canada Inc.
    Indication Bladder, overactive
    Submission type Resubmission #1
    Date submission received 2009-01-05
    Status Completed Submission status report
    Date recommendation issued 2009-06-17 Recommendation and reasons
    Recommendation List with criteria/condition

  153. Solifenacin succinate

    Brand name Vesicare
    Manufacturer Astellas Pharma Canada Inc.
    Indication Bladder, overactive
    Submission type Initial
    Date submission received 2006-07-24
    Status Completed Submission status report
    Date recommendation issued 2007-01-24 Recommendation and reasons
    Recommendation Do not list

  154. Somatropin (rDNA origin)

    Brand name Omnitrope
    Manufacturer Sandoz Canada Inc.
    Indication Growth hormone deficiency in children and adults
    Submission type Initial
    Date submission received 2009-06-12
    Status Completed Submission status report
    Date advice issued 2009-12-16 Advice - SEB

  155. Sorafenib tablets

    Brand name Nexavar
    Manufacturer Bayer Inc.
    Indication Renal cell carcinoma
    Submission type Initial
    Date submission received 2006-07-31
    Status Completed Submission status report
    Date recommendation issued 2007-02-28 Recommendation and reasons
    Recommendation Do not list

  156. Sunitinib

    Brand name Sutent
    Manufacturer Pfizer Canada Inc.
    Indication Gastrointestinal stromal tumour (GIST)
    Submission type Initial
    Date submission received 2006-07-20
    Status Completed Submission status report
    Date recommendation issued 2007-03-28 Recommendation and reasons
    Recommendation List with criteria/condition

  157. Sunitinib malate

    Brand name Sutent
    Manufacturer Pfizer Canada Inc.
    Indication Metastatic renal cell carcinoma
    Submission type Resubmission #1
    Date submission received 2006-09-20
    Status Completed Submission status report
    Date recommendation issued 2007-04-26 Recommendation and reasons
    Recommendation Do not list

  158. Tadalafil

    Brand name Adcirca
    Manufacturer Eli Lilly Canada Inc.
    Indication Pulmonary Arterial Hypertension
    Submission type Initial
    Date submission received 2010-02-05
    Status Active Submission status report

  159. Telbivudine

    Brand name Sebivo
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Hepatitis B (chronic)
    Submission type Initial
    Date submission received 2006-12-04
    Status Completed Submission status report
    Date recommendation issued 2007-09-26 Recommendation and reasons
    Recommendation Do not list

  160. Tenofovir disoproxil fumarate

    Brand name Viread
    Manufacturer Gilead Sciences Canada Inc.
    Indication Hepatitis B (Chronic)
    Submission type New Indication
    Date submission received 2008-10-02
    Status Completed Submission status report
    Date recommendation issued 2009-03-18 Recommendation and reasons
    Recommendation List with criteria/condition

  161. Tenofovir disoproxil fumarate

    Brand name Viread
    Manufacturer Gilead Sciences Canada Inc.
    Indication HIV infection
    Submission type Request for Advice
    Date submission received 2008-07-07
    Status Completed Submission status report

  162. Tenofovir disoproxil fumarate

    Brand name Viread
    Manufacturer Gilead Sciences Canada Inc.
    Indication HIV infection
    Submission type Resubmission #1
    Date submission received 2005-08-11
    Status Completed Submission status report
    Date recommendation issued 2006-03-15 Recommendation and reasons
    Recommendation List with criteria/condition

  163. Tenofovir disoproxil fumarate

    Brand name Viread
    Manufacturer Gilead Sciences Canada Inc.
    Indication HIV infection
    Submission type Initial
    Date submission received 2004-02-23
    Status Completed Submission status report
    Date recommendation issued 2004-08-25 Recommendation and reasons
    Recommendation Do not list

  164. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication Severe osteoporosis in women
    Submission type ACP Submission
    Date submission received 2009-10-23
    Status Active Submission status report

  165. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication Osteoporosis
    Submission type Resubmission #3
    Date submission received 2009-06-12
    Status Withdrawn Submission status report

  166. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication Osteoporosis
    Submission type Resubmission #2
    Date submission received 2008-12-18
    Status Withdrawn Submission status report

  167. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication Osteoporosis (glucocorticoid induced)
    Submission type New Indication
    Date submission received 2008-12-18
    Status Completed Submission status report
    Date recommendation issued 2009-07-22 Recommendation and reasons
    Recommendation Do not list

  168. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication Osteoporosis
    Submission type Resubmission #1
    Date submission received 2006-05-29
    Status Withdrawn Submission status report

  169. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication Osteoporosis
    Submission type Initial
    Date submission received 2004-06-08
    Status Completed Submission status report
    Date recommendation issued 2004-12-22 Recommendation and reasons
    Recommendation Do not list

  170. Tipranavir

    Brand name Aptivus
    Manufacturer Boehringer Ingelheim (Canada) Inc.
    Indication HIV infection
    Submission type Initial
    Date submission received 2005-12-15
    Status Completed Submission status report
    Date recommendation issued 2006-05-17 Recommendation and reasons
    Recommendation List with criteria/condition

  171. Tramadol hydrochloride

    Brand name Tridural
    Manufacturer Labopharm Inc.
    Indication Pain
    Submission type Initial
    Date submission received 2007-11-29
    Status Completed Submission status report
    Date recommendation issued 2008-04-17 Recommendation and reasons
    Recommendation Do not list

  172. Tramadol hydrochloride

    Brand name Ralivia
    Manufacturer Biovail Pharmaceuticals Canada
    Indication Pain
    Submission type Initial
    Date submission received 2007-10-29
    Status Completed Submission status report
    Date recommendation issued 2008-06-25 Recommendation and reasons
    Recommendation Do not list

  173. Tramadol hydrochloride

    Brand name Zytram XL
    Manufacturer Purdue Pharma
    Indication Pain
    Submission type Resubmission #1
    Date submission received 2007-03-15
    Status Completed Submission status report
    Date recommendation issued 2007-09-26 Recommendation and reasons
    Recommendation Do not list

  174. Tramadol hydrochloride

    Brand name Zytram XL
    Manufacturer Purdue Pharma
    Indication Acute pain
    Submission type Initial
    Date submission received 2006-11-03
    Status Withdrawn Submission status report

  175. Tramadol hydrochloride / acetaminophen

    Brand name Tramacet
    Manufacturer Janssen-Ortho Inc.
    Indication Acute pain
    Submission type Initial
    Date submission received 2006-10-02
    Status Completed Submission status report
    Date recommendation issued 2007-05-17 Recommendation and reasons
    Recommendation Do not list

  176. Travoprost and timolol maleate

    Brand name DuoTrav
    Manufacturer Alcon Canada Inc.
    Indication Glaucoma
    Submission type Initial
    Date submission received 2006-03-24
    Status Completed Submission status report
    Date recommendation issued 2006-08-24 Recommendation and reasons
    Recommendation List with criteria/condition

  177. Treprostinil sodium

    Brand name Remodulin
    Manufacturer Northern Therapeutics Inc.
    Indication Pulmonary arterial hypertension (NYHA Class III and IV patients)
    Submission type Resubmission #1
    Date submission received 2006-02-24
    Status Completed Submission status report
    Date recommendation issued 2006-07-20 Recommendation and reasons
    Recommendation List with criteria/condition

  178. Treprostinil sodium

    Brand name Remodulin
    Manufacturer Northern Therapeutics Inc.
    Indication Pulmonary arterial hypertension (NYHA Class III and IV patients)
    Submission type Initial
    Date submission received 2004-07-14
    Status Completed Submission status report
    Date recommendation issued 2004-11-17 Recommendation and reasons
    Recommendation Do not list

  179. Triptorelin pamoate

    Brand name Trelstar
    Manufacturer Watson Laboratories Inc.
    Indication Prostate cancer
    Submission type Initial
    Date submission received 2006-02-27
    Status Completed Submission status report
    Date recommendation issued 2006-07-20 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  180. Trospium chloride

    Brand name Trosec
    Manufacturer Oryx Pharmaceuticals Inc.
    Indication Bladder, overactive
    Submission type Initial
    Date submission received 2006-03-24
    Status Completed Submission status report
    Date recommendation issued 2006-08-24 Recommendation and reasons
    Recommendation List with criteria/condition

  181. Ustekinumab

    Brand name Stelara
    Manufacturer Janssen-Ortho Inc.
    Indication Psoriasis
    Submission type Initial
    Date submission received 2009-01-07
    Status Completed Submission status report
    Date recommendation issued 2009-06-17 Recommendation and reasons
    Recommendation List with criteria/condition

  182. Varenicline tartrate

    Brand name Champix
    Manufacturer Pfizer Canada Inc.
    Indication Smoking-cessation
    Submission type Initial
    Date submission received 2007-03-21
    Status Completed Submission status report
    Date recommendation issued 2007-08-16 Recommendation and reasons
    Recommendation List with criteria/condition

  183. Voriconazole

    Brand name VFEND
    Manufacturer Pfizer Canada Inc.
    Indication Candidemia
    Submission type Resubmission #2
    Date submission received 2006-03-24
    Status Completed Submission status report
    Date recommendation issued 2006-10-25 Recommendation and reasons
    Recommendation List with criteria/condition

  184. Voriconazole

    Brand name VFEND
    Manufacturer Pfizer Canada Inc.
    Indication Aspergillosis, invasive
    Submission type Resubmission #1
    Date submission received 2004-10-25
    Status Completed Submission status report
    Date recommendation issued 2005-04-14 Recommendation and reasons
    Recommendation List with criteria/condition

  185. Voriconazole

    Brand name VFEND
    Manufacturer Pfizer Canada Inc.
    Indication Aspergillosis, Invasive
    Submission type Initial
    Date submission received 2004-08-24
    Status Withdrawn Submission status report

  186. Ziprasidone hydrochloride

    Brand name Zeldox
    Manufacturer Pfizer Canada Inc.
    Indication Schizophrenia and related psychotic disorders
    Submission type Initial
    Date submission received 2008-01-10
    Status Completed Submission status report
    Date recommendation issued 2008-08-14 Recommendation and reasons
    Recommendation List with criteria/condition

  187. Zoledronic acid

    Brand name Aclasta
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Osteoporosis (postmenopausal women)
    Submission type Initial
    Date submission received 2007-11-29
    Status Completed Submission status report
    Date recommendation issued 2008-06-25 Recommendation and reasons
    Recommendation Do not list